Surveillance of in Vitro Activity of Ceftolozane-tazobactam Against Contemporary Nosocomial Gram-negative Pathogens Isolated in Russia
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 700
- 试验地点
- 1
- 主要终点
- To access ceftolozane-tazobactam activity against P. aeruginosa producing class A ESBL
研究概览
简要总结
Infections caused by resistant gram-negative bacteria are becoming increasingly prevalent and now constitute a serious threat to public health worldwide because they are difficult to treat and are associated with high morbidity and mortality rates. Among nosocomial infections, the most major threat represent infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative pathogens.
详细描述
Infections caused by resistant gram-negative bacteria are becoming increasingly prevalent and now constitute a serious threat to public health worldwide because they are difficult to treat and are associated with high morbidity and mortality rates. Among nosocomial infections, the most major threat represent infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative pathogens. The most problematic are the ESKAPE microorganisms, an acronym of the most frequently isolated MDR bacteria (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp).
Extended-spectrum β-lactamases (ESBLs) have emerged as a major source of antimicrobial resistance in gram-negative pathogens. Generally encoded by plasmid-borne genes, these enzymes confer resistance to penicillins, cephalosporins, and aztreonam. In addition, their presence in bacteria has been associated with resistance to other classes of nonpenicillin antibiotics, including fluoroquinolones, aminoglycosides, trimethoprim-sulfamethoxazole, and β-lactam/β-lactamase inhibitor combinations. Thus, ESBL-producing organisms often possess a multidrug resistance phenotype. Furthermore ESBL production has been associated with severe adverse clinical and economic outcomes, including increased mortality, increased length of stay, delay in the institution of effective therapy, decreased functional status on discharge, and increased cost of care.
The recent emergence and spread of infections caused by carbapenem-resistant Enterobacteriaceae (CRE) are concerning because carbapenems have represented a last line of defense against resistant strains of gram-negative pathogens [6]. The most clinically relevant carbapenemases in Enterobacteriaceae are the class D enzymes of the OXA-48 group, class A enzymes of the KPC type and the zinc-dependent class B metallo-β-lactamases (MβLs), represented mainly by the VIM, IMP, and NDM type.
Carbapenemase-producing Enterobacteria cause serious infections in debilitated and immunocompromised patients, in association with prolonged hospital stays and increased mortality rates, ranging from 24% to as high as 70%, depending on the study population [8,9]. Given the critical condition of these patients, treatment should be timely and rapidly efficacious. However, therapeutic options are obviously limited.
The environmental bacterium P. aeruginosa is one of the most important nosocomial pathogens, especially in intensive care units. Intrinsic and acquired antibiotic resistance makes P. aeruginosa one of the most difficult organisms to treat. The high intrinsic antibiotic resistance of P. aeruginosa is due to several mechanisms: a low outer membrane permeability, the production of an AmpC β-lactamase, and the presence of numerous genes coding for different multidrug resistance efflux pumps[10]. Loss of OprD is the most prevalent mechanism of resistance to carbapenems and is associated with resistance to imipenem and reduced susceptibility to meropenem [11].
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- — 至 90 Years(Child, Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •consecutive, non-duplicate (one per patient/episode of infection), gram-negative clinical isolates collected from patients with intra-abdominal, urinary tract, lower respiratory tract, and bloodstream nosocomial infections
排除标准
- •Non-Enterobacteriaceae isolates after reidentification
结局指标
主要结局
To access ceftolozane-tazobactam activity against P. aeruginosa producing class A ESBL
时间窗: 01.01.2017 - 31.10.2018
ceftolozane-tazobactam will demonstrate activity against P. aeruginosa isolates producing class A extended-spectrum beta-lactamases (ESBLs) and carbapenemases of GES type
To access ceftolozane-tazobactam activity against P. aeruginosa
时间窗: 01.01.2017 - 31.10.2018
ceftolozane-tazobactam will demonstrate activity against P. aeruginosa isolates of various genotypes including members of international high-risk clones
To determine the prevalence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) of molecular class A
时间窗: 01.01.2017 - 31.10.2018
the prevalence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) of molecular class A will be high
To access ceftolozane-tazobactam activity against many multidrug-resistant isolates of P. aeruginosa,
时间窗: 01.01.2017 - 31.10.2018
ceftolozane-tazobactam will demonstrate activity against many multidrug-resistant isolates of P. aeruginosa, including cephalosporin- and carbapenem-resistant isolates that do not produce a metallo-beta-lactamase
To access ceftolozane-tazobactam activity against many Eterobacteriaceae isolates produsing ESBLs and/or OXA-48-like enzymes
时间窗: 01.01.2017 - 31.10.2018
ceftolozane-tazobactam will demonstrate activity againt many Eterobacteriaceae isolates produsing ESBLs and/or OXA-48-like enzymes
To determine the molecular class D (OXA-48-like) enzymes carbapenemases in Enterobacteriaceae in Russia and the prevalence of carbapenemases of molecular classes A and B
时间窗: 01.01.2017 - 31.10.2018
molecular class D (OXA-48-like) enzymes will be the most common carbapenemases in Enterobacteriaceae in Russia and the prevalence of carbapenemases of molecular classes A and B will be limited
次要结局
未报告次要终点
